Form 4: Inovio Pharmaceuticals, Inc. (INO), Shepard Jay, transaction 01/15/2021

Summary

Jay Shepard, a Director of INOVIO PHARMACEUTICALS, INC. [ INO ], reports on this Form 4 that 4,274 Restricted Stock Units converted into 4,274 shares of Common Stock on 01/15/2021. The explanation states each unit is a contingent right to receive one share, and that the 12,821 units vest as 4,274 shares on January 15, 2021, 4,274 on January 15, 2022 and 4,273 on January 15, 2023. Vested units can be settled in shares, cash or a combination of both, and 8,547 units remain after the transaction. The signature reads /s/ Jay P. Shepard, 01/15/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Shepard Jay (Last) (First) (Middle) 660 W. GERMANTOWN PIKE SUITE 110 (Street) PLYMOUTH MEETING PA 19462 (City) (State) (Zip) | Shepard Jay | (Last) | (First) | (Middle) | 660 W. GERMANTOWN PIKE SUITE 110 | PLYMOUTH MEETING | PA | 19462 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 01/15/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 01/15/2021 | M | 4,274 | A | (1) | 4,274 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Restricted Stock Unit | (1) | 01/15/2021 | M | 4,274 | (1) | (1) | Common Stock | 4,274 | $ 0 | 8,547 | D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
Remarks:
/s/ Jay P. Shepard | 01/15/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_INO_4_filed2021-01-15_0001055726-21-000003.xml

Size

16,308 bytes

SHA-256

bfb1c31766d828f7d5416bab9b6746453692bb8b13edebeeb9db51a9a2303e23

Our copy

SEC_INO_4_filed2021-01-15_0001055726-21-000003.xml

Original

www.sec.gov